gpointstudio /
15 October 2015Americas

Ranbaxy and Allergan reach acne drug settlement

Pharmaceutical company Ranbaxy Laboratories, a subsidiary of Sun Pharma, has confirmed it has settled a patent lawsuit filed against Allergan.

The dispute concerned Allergan’s attempt to market a generic version of the Absorica  (isotretinoin capsules) drug, which is used to treat acne.

Under the terms of agreement, Allergan may begin selling a generic on December 27, 2020, nine months before the expiration of all the patents covering the drug.

Further details of the agreement have not been publicly disclosed. The agreement is subject to review by both the US Federal Trade Commission and the US Department of Justice.

Ranbaxy had filed the complaint against Allergan in October 2013 at the US District Court for the District of New Jersey, alleging infringement of one patent, US number 8,367,102.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at